Prevalence of Migraine in the Elderly: A Narrated Review

Wijeratne, Tissa; Tang, Huiliang Melissa; Crewther, David P.

doi:10.1159/000494758

Cited by 39 publications

(48 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The clinical features of migraine change in older age. Headache is less intense, and aura symptoms frequently become more prominent and sometimes even the only or the most bothersome feature of migraine (12). Depending on age, about 7-23% of migraine sufferers have migraine with aura (7).…”

Section: Introductionmentioning

confidence: 99%

Prevalence and risk factors of migraine and non-migraine headache in older people – results of the Heinz Nixdorf Recall study

et al. 2020

View full text Add to dashboard Cite

Background The prevalence of migraine and non-migraine headache declines with age. Methods Data from the third visit (2011–2015) of the population-based Heinz Nixdorf Recall study were analysed (n = 2038, 51% women, 65–86 years). Possible risk factors for headache activity (obesity, education, smoking, sports, alcohol, partnership status, living alone, having children, sleep quality, depression, hypertension, diabetes mellitus, stroke, coronary heart disease, medication), and headache symptoms were assessed. We estimated the lifetime prevalence and the prevalence of current active headache of migraine with and without aura, and non-migraine headache. The associations between possible risk factors and headache activity (active vs. inactive) were estimated by age and sex-adjusted odds ratios and 95% confidence intervals (OR [95% CI]) using multiple logistic regression. Results The lifetime prevalence of migraine was 28.6% (n = 584). One hundred and ninety-two (9.4%) had still-active migraine, 168 (3.5%) had migraine with aura, and 416 (5.9%) had migraine without aura. One hundred and sixty-eight (8.2%) had “episodic infrequent migraine, 0–8 headache days/month”, 10 (0.5%) had “episodic frequent migraine, 9–14 headache days/month”, and five (0.2%) had “chronic migraine, ≥15 headache days/month”. Overall, 10 (0.5%) had “chronic headache, any headache on ≥15 days/month”. Female gender and younger age were the most important associated migraine risk factors. Depression (1.62 [1.06; 2.47]) and poor sleep (1.06 [1.00; 1.12]) were associated with migraine and headache activity in general. Antihypertensives were associated with headache remission (0.80 [0.64; 1.00]). Additionally, undertaking less sports (0.72 [0.51; 1.03]) was associated with higher migraine activity. Conclusions Headaches and migraines are not rare in the older population. They are related to mood and sleep disturbance, and migraine even to less physical activity. Antihypertensives are related to headache remission.

show abstract

Section: Introductionmentioning

confidence: 99%

Prevalence and risk factors of migraine and non-migraine headache in older people – results of the Heinz Nixdorf Recall study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Several reports have shown that the clinical characteristics of migraine, such as attack severity and disease profile, can be different in older patients [10,15,16]. As a person with migraine ages, their brain can be metabolically and physically altered due to their disease [22][23][24].…”

Section: Discussionmentioning

confidence: 99%

“…While migraine can be experienced by people of all ages [7,10], the studies analyzed here enrolled patients with a maximum age of 65 years. However, the safety of galcanezumab in an older population was also addressed in a previous study of galcanezumab in patients with osteoarthritis.…”

Section: Discussionmentioning

confidence: 99%

“…While migraine is most prevalent in people aged 25 to 55 years [6], many people over the age of 55 years also experience migraine attacks [7][8][9], with the one-year prevalence of migraine among older adults being reported as approximately 10% [10]. However, diagnosis of migraine typically occurs before the age of 50 years and the prevalence of migraine tends to decrease with age [10,11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

Stauffer

Turner²,

Kemmer

et al. 2020

J Headache Pain

View full text Add to dashboard Cite

Background: Migraine clinical profile may change with age, making it necessary to verify that migraine treatments are equally safe and effective in older patients. These analyses evaluated the effects of patient age on the pharmacokinetics (PK), efficacy, and safety of galcanezumab for prevention of migraine. Methods: Analyses included efficacy data from three double-blind phase 3 clinical trials: two 6-month studies in episodic migraine (EVOLVE-1, EVOLVE-2: N = 1773) and one 3-month study in chronic migraine (REGAIN:N = 1113). Patients were randomized 2:1:1 to placebo, galcanezumab 120 mg, or galcanezumab 240 mg. Safety and PK data included additional phase 2 and phase 3 trials for a larger sample size of patients > 60 years (range = 18-65 for all studies). Subgroup analyses assessed efficacy measures, adverse event (AE) occurrence, and cardiovascular measurement changes by patient age group. Galcanezumab PK were evaluated using a population analysis approach, where age was examined as a potential covariate on apparent clearance (CL/F) and apparent volume of distribution (V/F) of galcanezumab. Results: Numbers of baseline monthly migraine headache days were similar across age groups. There were no statistically significant treatment-by-age group interactions for any efficacy measures, except in episodic migraine studies where older patients appeared to have a larger reduction than younger patients in the number of monthly migraine headache days with acute medication use. Age (18-65) had a minimal effect on CL/F, and no effect on V/ F. Galcanezumab-treated patients ≥60 years experienced no clinically meaningful increases in blood pressure and no increased frequency in treatment-emergent AEs, discontinuations due to AEs, serious adverse events (SAEs) overall, or cardiovascular SAEs, compared to age-matched placebo-treated patients.

show abstract

“…The prevalence of migraine in children increases with age [5]. And the annual prevalence of migraine in the elderly is about 10% [6]. Migraine is the main cause of disability in the world, the number of years of disability-adjusted life lost caused by migraine has reached one third [7].…”

Section: Introductionmentioning

confidence: 99%

Knowledge Mapping of Migraine: a Bibliometric Analysis (2000-2019)

Zhao

2021

Preprint

View full text Add to dashboard Cite

Background: There has been rapid development of migraine research in the past 20 years in China and around the world. We analyzed the development trend of migraine research, and made a bibliometric analysis on the growth trend of the total number of publications, countries, institutions, authors, cited references and keywords from 2000 to 2009 and 2010 to 2019 by applying visualization software, and constructed the relevant knowledge map, and found the trends and hot spots in the field through comparison. Methods: Retrieved the literature on migraine in the Web of Science database from 2000-2009 and 2010-2019 respectively, and then utilized CiteSpace to conduct bibliometric analysis to acquire the knowledge mapping. Results: The total number of publications each year has increased year by year, and the average annual growth rate from 2000 to 2009 was 7.999%, while from 2010 to 2019 was 5.348%, with a faster growth rate from 2000 to 2009. According to the cluster analysis of institutions, authors, cited references, and keywords, 10/11, 12/11, 12/11, and 8/9 categories were obtained from 2000 to 2009 and 2010 to 2019 respectively. The most productive countries, institutions, and authors are the USA, Albert Einstein College of Medicine, and Lipton RB from 2000 to 2009 and 2010 to 2019, whose frequency is 4274/7107, 322/592, and 279/472 respectively. However, the most important of them are Belgium/ Pakistan, Houston Headache Clin/ Amgen Inc, and Lipton RB/ Klatt J, owing to their highest centrality, they are 1.20/1.08, 1.13/1.32, and 1.22/0.89 separately. Moreover, Cited references that contributed to the most co-citations are Silberstein SD (2004)/ Bes A (2013) from 2000 to 2009 and 2010 to 2019, however, the most vital cited reference is Welch KMA (2001)/ Goadsby PJ (2017). Keywords such as migraine, headache, prevalence, and the double blind are the most frequently used. But prevalence is the crucial keyword. In the cluster analysis of institutions, authors, cited references, and keywords from 2000 to 2009 and 2010 to 2019, the more convincing research categories are potential anti-migraine agent/ chronic migration prevention, reducing headache recurrence/ following symptomatic treatment, to-left shunt/ placebo controlled phase, spectrum study/ family study hemiplegic migraine, with S values of 0.952/0.956, 0.985/0/986, 0.981/0.970 and 0.985/0.982 respectively. Furthermore, the hotspots in this field are “stimulation”, “triptan” from 2000 to 2009 and 2010 to 2019. Conclusion: Based on the bibliometric analysis in the past 20 years, the knowledge mapping of the country, institution, author, cited reference, and the keyword is gained, which has an important guiding significance for quickly and accurately positioning the trend in this field.

show abstract

Prevalence of Migraine in the Elderly: A Narrated Review

Cited by 39 publications

References 70 publications

Prevalence and risk factors of migraine and non-migraine headache in older people – results of the Heinz Nixdorf Recall study

Prevalence and risk factors of migraine and non-migraine headache in older people – results of the Heinz Nixdorf Recall study

Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials

Knowledge Mapping of Migraine: a Bibliometric Analysis (2000-2019)

Contact Info

Product

Resources

About